|
19.01.2018 16:10:00
|
Quest Diagnostics Named One of 2018 "World's Most Admired Companies" by Fortune Magazine for Third Consecutive Year
SECAUCUS, N.J., Jan. 19, 2018 /PRNewswire/ -- Quest Diagnostics (NYSE: DGX), the world's leading provider of diagnostic information services, today announced that it has been named one of the "World's Most Admired Companies" for 2018 by Fortune for the third consecutive year.
The annual survey designated Quest Diagnostics as one of only five companies in the "Health Care: Pharmacy and Other Services" industry to attain Most Admired status. The company advanced one spot in the industry ranking from last year.
"We are honored to be included for the third consecutive year," said Steve Rusckowski, Chairman, President and CEO. "This is a tribute to our 45,000 employees who are committed to excellence in everything they do, enabling us to promote a healthier world, build value, and create an inspiring workplace."
Fortune's "World's Most Admired Companies" list is based on surveys of 680 companies from 29 countries, asking executives, directors, and analysts to rate enterprises in their own industry on nine criteria, from investment value and quality of management and products to social responsibility and ability to attract talent.
About Quest Diagnostics
Quest Diagnostics empowers people to take action to improve health outcomes. Derived from the world's largest database of clinical lab results, our diagnostic insights reveal new avenues to identify and treat disease, inspire healthy behaviors and improve health care management. Quest annually serves one in three adult Americans and half the physicians and hospitals in the United States, and our 45,000 employees understand that, in the right hands and with the right context, our diagnostic insights can inspire actions that transform lives. www.QuestDiagnostics.com.
View original content with multimedia:http://www.prnewswire.com/news-releases/quest-diagnostics-named-one-of-2018-worlds-most-admired-companies-by-fortune-magazine-for-third-consecutive-year-300585255.html
SOURCE Quest Diagnostics
Der finanzen.at Ratgeber für Aktien!
Wenn Sie mehr über das Thema Aktien erfahren wollen, finden Sie in unserem Ratgeber viele interessante Artikel dazu!
Jetzt informieren!
Nachrichten zu Quest Diagnostics Inc.mehr Nachrichten
|
19.11.24 |
S&P 500-Wert Quest Diagnostics-Aktie: So viel Gewinn hätte eine Investition in Quest Diagnostics von vor einem Jahr abgeworfen (finanzen.at) | |
|
15.11.24 |
S&P 500-Handel aktuell: So entwickelt sich der S&P 500 aktuell (finanzen.at) | |
|
12.11.24 |
S&P 500-Papier Quest Diagnostics-Aktie: So viel hätte eine Investition in Quest Diagnostics von vor 10 Jahren abgeworfen (finanzen.at) | |
|
05.11.24 |
S&P 500-Titel Quest Diagnostics-Aktie: So viel hätten Anleger an einem Quest Diagnostics-Investment von vor 5 Jahren verdient (finanzen.at) | |
|
29.10.24 |
S&P 500-Titel Quest Diagnostics-Aktie: So viel hätten Anleger an einem Quest Diagnostics-Investment von vor 3 Jahren verdient (finanzen.at) | |
|
22.10.24 |
Schwacher Wochentag in New York: S&P 500 zum Ende des Dienstagshandels im Minus (finanzen.at) | |
|
22.10.24 |
S&P 500 aktuell: S&P 500 notiert im Plus (finanzen.at) | |
|
22.10.24 |
Schwacher Handel in New York: S&P 500 am Mittag in der Verlustzone (finanzen.at) |
Analysen zu Quest Diagnostics Inc.mehr Analysen
ETF-Sparplan
Oskar ist der einfache und intelligente ETF-Sparplan. Er übernimmt die ETF-Auswahl, ist steuersmart, transparent und kostengünstig.